ANK3作为拉法新治疗难治性抑郁症的新型遗传生物标志物:ENLIGHTEN随机临床试验
这项生物标志物引导的2b期随机双盲安慰剂对照试验在58个中心评估了189例ANK3阳性的难治性抑郁症患者,比较拉法新1mg、2mg与安慰剂。
要点
- ANK3阳性难治性抑郁症患者中,拉法新较安慰剂显著改善MADRS评分。
- 拉法新组因不良事件停药比例为4.0%,低于安慰剂组的14.1%。
- 这是精神病学领域首个成功的前瞻性遗传生物标志物引导试验。
核心结论
- 拉法新在ANK3阳性的难治性抑郁症患者中有效且耐受性良好,改善具有临床意义和统计学显著性,提示ANK3可作为拉法新的预测性遗传生物标志物。
研究设计与样本
- 生物标志物引导的随机双盲安慰剂对照2b期临床试验,于2022年7月至2024年3月在58个中心开展,评估1967例患者资格后随机分配189例ANK3阳性难治性抑郁症患者。
- 患者按1:1:1随机接受每日口服拉法新1mg、拉法新2mg或安慰剂,研究者、患者、评估者和申办方对ANK3状态和治疗分配均设盲。
主要发现
- 188例患者接受研究药物(平均年龄43.2岁,标准差14.8;女性119例,占63.3%),186例至少接受1剂研究药物并有1次随机化后疗效评估。
- 所有次要终点也观察到统计学显著改善。
- 不良事件可耐受,有意义事件发生率低;导致停药的不良事件在拉法新组发生于5例(4.0%),安慰剂组9例(14.1%)。
关键数值与推荐
- 主要结局为蒙哥马利-奥斯伯格抑郁评定量表(MADRS)总分从基线至第42天的变化。
临床怎么用
- 对于ANK3阳性的难治性抑郁症患者,拉法新可能作为精准医学选择,治疗需关注不良事件及停药风险。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: This study represents a first successful use of a genetic biomarker to select potential responders in a prospective study in psychiatry. Liafensine, a triple reuptake inhibitor, may become a new precision medicine for treatment-resistant depression (TRD), a major unmet medical need. OBJECTIVE: To determine whether ANK3-positive patients with TRD benefit from a 1-mg and/or 2-mg daily oral dose of liafensine, compared with placebo, in a clinical trial. DESIGN, SETTING, AND PARTICIPANTS: A novel pharmacogenomic biomarker, ANK3, was discovered as a predictor of liafensine's efficacy retrospectively. In this biomarker-guided, randomized, double-blind, placebo-controlled, phase 2b clinical trial conducted at 58 sites from July 2022 through March 2024, 1967 patients were assessed for eligibility and 189 ANK3-positive patients with TRD were randomized. Key exclusion criteria included specified disorders, concomitant medications, or organ dysfunction. Investigators, patients, raters, and sponsors were blinded to ANK3 status and treatment. Data analysis was performed from March 26 to April 23, 2024. INTERVENTIONS: Patients were randomized 1:1:1 to once-daily oral liafensine, 1 mg; once-daily oral liafensine, 2 mg; or oral placebo once daily. MAIN OUTCOMES AND MEASURES: The primary outcome was the Montgomery-Åsberg Depression Rating Scale (MADRS) total score change from baseline to day 42. RESULTS: Of the 189 ANK3-positive patients with TRD who were randomized, 188 received study drug (mean [SD] age, 43.2 [14.8] years; 119 [63.3%] female), and 186 had at least 1 dose of study drug and 1 postrandomization efficacy evaluation. The mean (SE) MADRS score change in these patients was -15.4 (0.9) for liafensine (including both 1- and 2-mg doses) vs -11.0 (1.3) for placebo (mean treatment difference, -4.4; 95% CI, -7.6 to -1.3; P = .006). Statistically significant improvements were also seen in all secondary end points. Adverse events were tolerable, with low rates of meaningful events. Adverse events leading to discontinuation of treatment occurred in 5 patients (4.0%) receiving liafensine and 9 (14.1%) receiving placebo. CONCLUSIONS AND RELEVANCE: Liafensine was efficacious and well tolerated in ANK3-positive patients with TRD, with clinically meaningful and statistically significant improvements over placebo suggesting ANK3 as a predictive genetic biomarker for liafensine. This represents a first successful prospective genetic biomarker-guided trial in psychiatry. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05113771.
引用
- Wang G, Aguado M, Spear MA, et al. ANK3 as a Novel Genetic Biomarker for Liafensine in Treatment-Resistant Depression: The ENLIGHTEN Randomized Clinical Trial. JAMA Psychiatry. 2025. PMID: 40928787. doi:10.1001/jamapsychiatry.2025.2416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。